| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (replaced TA371) |
|
Medicine details |
|
| Medicine name | trastuzumab emtansine (Kadcyla®) |
| Formulation | 100 mg, 160 mg powder for concentrate for solution for infusion |
| Reference number | 1390 |
| Indication | As a single agent, for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/02/2014 |
| NICE guidance | |